| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | KALOCYTE INC | 670 W BALTIMORE ST | BALTIMORE | MD | 21201-1514 | BALTIMORE CITY | USA | R44HL135965 | ErythroMer: Nanoscale BioSynthetic Red Cell Substitute | 000 | 5 | NIH | 10/30/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $997,590 ) |
| | 2024 | 2024 | KALOCYTE INC | 670 W BALTIMORE ST | BALTIMORE | MD | 21201-1514 | BALTIMORE CITY | USA | R44HL135965 | ErythroMer: Nanoscale BioSynthetic Red Cell Substitute | 000 | 5 | NIH | 8/1/2024 | $997,590 |
| | 2024 | 2021 | KALOCYTE INC | 670 W BALTIMORE ST | BALTIMORE | MD | 21201-1514 | BALTIMORE CITY | USA | SB1HL135965 | Manufacturing Scale-up, Purification, and Analytical Method Development, Validation and Qualification for KC1003, Key Precursor for ErythroMer (RBC substitute) | 000 | 4 | NIH | 10/18/2023 | $0 |
| | 2024 | 2021 | KALOCYTE INC | 670 W BALTIMORE ST | BALTIMORE | MD | 21201-1514 | BALTIMORE CITY | USA | SB1HL135965 | Manufacturing Scale-up, Purification, and Analytical Method Development, Validation and Qualification for KC1003, Key Precursor for ErythroMer (RBC substitute) | 001 | 4 | NIH | 3/22/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,050,000 ) |
| | 2023 | 2023 | KALOCYTE INC | 670 W BALTIMORE ST | BALTIMORE | MD | 21201-1514 | BALTIMORE CITY | USA | R44HL135965 | ErythroMer: Nanoscale BioSynthetic Red Cell Substitute | 001 | 4 | NIH | 6/21/2023 | $0 |
| | 2023 | 2023 | KALOCYTE INC | 670 W BALTIMORE ST | BALTIMORE | MD | 21201-1514 | BALTIMORE CITY | USA | R44HL135965 | ErythroMer: Nanoscale BioSynthetic Red Cell Substitute | 000 | 4 | NIH | 5/19/2023 | $1,050,000 |
| | 2023 | 2020 | KALOCYTE INC | 670 W BALTIMORE ST | BALTIMORE | MD | 21201-1514 | BALTIMORE CITY | USA | R43HL151073 | Rapid Reconstitution of a Lyophilized, Bio-inspired, Artificial Red Blood Cell | 000 | 1 | NIH | 11/15/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | KALOCYTE INC | 670 W BALTIMORE ST HSRF III FL 8 | BALTIMORE | MD | 21201 | BALTIMORE CITY | USA | SB1HL135965 | Manufacturing Scale-up, Purification, and Analytical Method Development, Validation and Qualification for KC1003, Key Precursor for ErythroMer (RBC substitute) | 000 | 4 | NIH | 3/7/2022 | $0 |
| | 2022 | 2020 | KALOCYTE INC | 670 W BALTIMORE ST HSRF III FL 8 | BALTIMORE | MD | 21201 | BALTIMORE CITY | USA | R43HL151073 | Rapid Reconstitution of a Lyophilized, Bio-inspired, Artificial Red Blood Cell | 000 | 1 | NIH | 2/14/2022 | $0 |
| | 2022 | 2019 | KALOCYTE INC | 670 W BALTIMORE ST HSRF III FL 8 | BALTIMORE | MD | 21201 | BALTIMORE CITY | USA | R42HL135965 | ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute | 000 | 3 | NIH | 11/4/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $499,999 ) |
| | 2021 | 2021 | KALOCYTE INC | 670 W BALTIMORE ST HSRF III FL 8 | BALTIMORE | MD | 21201 | BALTIMORE CITY | USA | SB1HL135965 | Manufacturing Scale-up, Purification, and Analytical Method Development, Validation and Qualification for KC1003, Key Precursor for ErythroMer (RBC substitute) | 000 | 4 | NIH | 7/28/2021 | $499,999 |
| | 2021 | 2019 | KALOCYTE INC | 670 W BALTIMORE ST HSRF III FL 8 | BALTIMORE | MD | 21201 | BALTIMORE CITY | USA | R42HL135965 | ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute | 000 | 3 | NIH | 11/29/2020 | $0 |
| | 2021 | 2017 | KALOCYTE INC | 670 W BALTIMORE ST HSRF III FL 8 | BALTIMORE | MD | 21201 | BALTIMORE CITY | USA | R42HL135965 | ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute | 001 | 1 | NIH | 7/30/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $373,216 ) |
| | 2020 | 2020 | KALOCYTE INC | 20 S SARAH ST | SAINT LOUIS | MO | 63108-2819 | SAINT LOUIS CITY | USA | R43HL151073 | Rapid Reconstitution of a Lyophilized, Bio-inspired, Artificial Red Blood Cell | 000 | 1 | NIH | 4/30/2020 | $373,216 |
| | 2020 | 2020 | KALOCYTE INC | 670 W BALTIMORE ST HSRF III FL 8 | BALTIMORE | MD | 21201 | BALTIMORE CITY | USA | R43HL151073 | Rapid Reconstitution of a Lyophilized, Bio-inspired, Artificial Red Blood Cell | 001 | 1 | NIH | 8/5/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $788,480 ) |
| | 2019 | 2019 | KALOCYTE INC | 20 S SARAH ST | SAINT LOUIS | MO | 63108-2819 | SAINT LOUIS CITY | USA | R42HL135965 | ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute | 001 | 3 | NIH | 6/28/2019 | $788,480 |
| | 2019 | 2018 | KALOCYTE INC | 4320 FOREST PARK AVE STE 304 | SAINT LOUIS | MO | 63108-2979 | SAINT LOUIS CITY | USA | R42HL135965 | ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute | 000 | 2 | NIH | 3/5/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $833,728 ) |
| | 2018 | 2018 | KALOCYTE INC | 4320 FOREST PARK AVE STE 304 | SAINT LOUIS | MO | 63108-2979 | SAINT LOUIS CITY | USA | R42HL135965 | ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute | 000 | 2 | NIH | 6/15/2018 | $833,728 |
|
| Issue Date FY: 2017 ( Subtotal = $397,622 ) |
| | 2017 | 2017 | KALOCYTE INC | 4320 FOREST PARK AVE STE 304 | SAINT LOUIS | MO | 63108-2979 | SAINT LOUIS CITY | USA | R42HL135965 | ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute | 000 | 1 | NIH | 5/11/2017 | $397,622 |
|
|
